1
|
Wang L, Yu Z, Zhang J, Guo J. Nanoformulations of chemotherapeutic activators of the cGAS-STING pathway in tumor chemoimmunotherapy. Drug Discov Today 2024; 29:103892. [PMID: 38272174 DOI: 10.1016/j.drudis.2024.103892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 01/08/2024] [Accepted: 01/16/2024] [Indexed: 01/27/2024]
Abstract
Chemotherapeutic drugs to activate the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway have been exploited for tumor chemoimmunotherapy. The clinical translation of chemotherapeutic cGAS-STING activators is hindered by the lack of safe, efficient, and specific delivery strategies. Nanodrug delivery systems (NDDS) designed for reducing toxic effects and improving transport effectiveness potentiate in vivo delivery of chemotherapeutic cGAS-STING activators. cGAS-STING monotherapy often encounters tumor resistance without providing satisfactory therapeutic benefit; therefore combination therapy is desirable. This review describes NDDS strategies for surmounting delivery obstacles of chemotherapeutic cGAS-STING activators and highlights combinatorial regimens, which utilize therapeutics that work by different mechanisms, for optimal therapy.
Collapse
Affiliation(s)
- Lingzhi Wang
- School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China
| | - Zhuo Yu
- Department of Hepatopathy, Shuguang Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
| | - Jihong Zhang
- Hematology Laboratory, Shengjing Hospital of China Medical University, Shenyang 110022, China.
| | - Jianfeng Guo
- School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
| |
Collapse
|
2
|
Sikder A, Vambhurkar G, Amulya E, Bagasariya D, Famta P, Shah S, Khatri DK, Singh SB, Sinha VR, Srivastava S. Advancements in redox-sensitive micelles as nanotheranostics: A new horizon in cancer management. J Control Release 2022; 349:1009-1030. [PMID: 35961470 DOI: 10.1016/j.jconrel.2022.08.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Revised: 08/05/2022] [Accepted: 08/05/2022] [Indexed: 12/24/2022]
Abstract
World Health Organisation (WHO) delineated cancer as one of the foremost reasons for mortality with 10 million deaths in the year 2020. Early diagnosis and effective drug delivery are of utmost importance in cancer management. The entrapment of both bio-imaging dyes and drugs will open novel avenues in the area of tumor theranostics. Elevated levels of reactive oxygen species (ROS) and glutathione (GSH) are the characteristic features of the tumor microenvironment (TME). Researchers have taken advantage of these specific TME features in recent years to develop micelle-based theranostic nanosystems. This review focuses on the advantages of redox-sensitive micelles (RSMs) and supramolecular self-assemblies for tumor theranostics. Key chemical linkers employed for the tumor-specific release of the cargo have been discussed. In vitro characterisation techniques used for the characterization of RSMs have been deliberated. Potential bottlenecks that may present themselves in the bench-to-bedside translation of this technology and the regulatory considerations have been deliberated.
Collapse
Affiliation(s)
- Anupama Sikder
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Ganesh Vambhurkar
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Etikala Amulya
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Deepkumar Bagasariya
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Paras Famta
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Saurabh Shah
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Dharmendra Kumar Khatri
- Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Shashi Bala Singh
- Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - V R Sinha
- Department of Pharmaceutics, University Institute of Pharmaceutical Sciences (UIPS), Panjab University, Chandigarh, India
| | - Saurabh Srivastava
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
| |
Collapse
|
3
|
Khan N, Ruchika, Kumar Dhritlahre R, Saneja A. Recent advances in dual-ligand targeted nanocarriers for cancer therapy. Drug Discov Today 2022; 27:2288-2299. [DOI: 10.1016/j.drudis.2022.04.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 03/05/2022] [Accepted: 04/11/2022] [Indexed: 12/30/2022]
|
4
|
Khonina TG, Nikitina EY, Germov AY, Goloborodsky BY, Mikhalev KN, Bogdanova EA, Tishin DS, Demin AM, Krasnov VP, Chupakhin ON, Charushin VN. Individual iron(iii) glycerolate: synthesis and characterisation. RSC Adv 2022; 12:4042-4046. [PMID: 35425460 PMCID: PMC8981226 DOI: 10.1039/d1ra08485b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Accepted: 01/25/2022] [Indexed: 11/30/2022] Open
Abstract
Iron(ii) and iron(iii) salts of strong acids form iron glycerolates on heating at 180 °C with glycerol in the presence of an equivalent amount of alkali. Individual iron(iii) glycerolate was obtained for the first time. When Fe3O4 magnetic nanoparticles were heated with glycerol, an iron(iii) glycerolate shell was formed on their surface. Individual iron(iii) glycerolate was obtained and characterized; a method for the preparation of an iron(iii) glycerolate shell on the surface of Fe3O4 MNPs was proposed.![]()
Collapse
Affiliation(s)
- Tat'yana G. Khonina
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences, Ural Branch, Yekaterinburg 620108, Russia
| | - Elena Yu. Nikitina
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences, Ural Branch, Yekaterinburg 620108, Russia
| | - Alexander Yu. Germov
- Miheev Institute of Metal Physics, Russian Academy of Sciences, Ural Branch, Yekaterinburg 620108, Russia
| | - Boris Yu. Goloborodsky
- Miheev Institute of Metal Physics, Russian Academy of Sciences, Ural Branch, Yekaterinburg 620108, Russia
| | - Konstantin N. Mikhalev
- Miheev Institute of Metal Physics, Russian Academy of Sciences, Ural Branch, Yekaterinburg 620108, Russia
| | - Ekaterina A. Bogdanova
- Institute of Solid State Chemistry, Russian Academy of Sciences, Ural Branch, Yekaterinburg 620108, Russia
| | - Denis S. Tishin
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences, Ural Branch, Yekaterinburg 620108, Russia
| | - Alexander M. Demin
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences, Ural Branch, Yekaterinburg 620108, Russia
| | - Victor P. Krasnov
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences, Ural Branch, Yekaterinburg 620108, Russia
| | - Oleg N. Chupakhin
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences, Ural Branch, Yekaterinburg 620108, Russia
- Institute of Chemical Technology, Ural Federal University, Yekaterinburg 620002, Russia
| | - Valery N. Charushin
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences, Ural Branch, Yekaterinburg 620108, Russia
- Institute of Chemical Technology, Ural Federal University, Yekaterinburg 620002, Russia
| |
Collapse
|
5
|
Lynch MJ, Gobbo OL. Advances in Non-Animal Testing Approaches towards Accelerated Clinical Translation of Novel Nanotheranostic Therapeutics for Central Nervous System Disorders. NANOMATERIALS (BASEL, SWITZERLAND) 2021; 11:2632. [PMID: 34685073 PMCID: PMC8538557 DOI: 10.3390/nano11102632] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 09/21/2021] [Accepted: 10/01/2021] [Indexed: 12/11/2022]
Abstract
Nanotheranostics constitute a novel drug delivery system approach to improving systemic, brain-targeted delivery of diagnostic imaging agents and pharmacological moieties in one rational carrier platform. While there have been notable successes in this field, currently, the clinical translation of such delivery systems for the treatment of neurological disorders has been limited by the inadequacy of correlating in vitro and in vivo data on blood-brain barrier (BBB) permeation and biocompatibility of nanomaterials. This review aims to identify the most contemporary non-invasive approaches for BBB crossing using nanotheranostics as a novel drug delivery strategy and current non-animal-based models for assessing the safety and efficiency of such formulations. This review will also address current and future directions of select in vitro models for reducing the cumbersome and laborious mandate for testing exclusively in animals. It is hoped these non-animal-based modelling approaches will facilitate researchers in optimising promising multifunctional nanocarriers with a view to accelerating clinical testing and authorisation applications. By rational design and appropriate selection of characterised and validated models, ranging from monolayer cell cultures to organ-on-chip microfluidics, promising nanotheranostic particles with modular and rational design can be screened in high-throughput models with robust predictive power. Thus, this article serves to highlight abbreviated research and development possibilities with clinical translational relevance for developing novel nanomaterial-based neuropharmaceuticals for therapy in CNS disorders. By generating predictive data for prospective nanomedicines using validated in vitro models for supporting clinical applications in lieu of requiring extensive use of in vivo animal models that have notable limitations, it is hoped that there will be a burgeoning in the nanotherapy of CNS disorders by virtue of accelerated lead identification through screening, optimisation through rational design for brain-targeted delivery across the BBB and clinical testing and approval using fewer animals. Additionally, by using models with tissue of human origin, reproducible therapeutically relevant nanomedicine delivery and individualised therapy can be realised.
Collapse
Affiliation(s)
- Mark J. Lynch
- School of Pharmacy and Pharmaceutical Sciences, Panoz Building, Trinity College Dublin, D02 PN40 Dublin, Ireland
| | - Oliviero L. Gobbo
- School of Pharmacy and Pharmaceutical Sciences, Panoz Building, Trinity College Dublin, D02 PN40 Dublin, Ireland
| |
Collapse
|
6
|
Abbasi Kajani A, Haghjooy Javanmard S, Asadnia M, Razmjou A. Recent Advances in Nanomaterials Development for Nanomedicine and Cancer. ACS APPLIED BIO MATERIALS 2021; 4:5908-5925. [PMID: 35006909 DOI: 10.1021/acsabm.1c00591] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Cancer is considered one of the leading causes of death, with a growing number of cases worldwide. However, the early diagnosis and efficient therapy of cancer have remained a critical challenge. The emergence of nanomedicine has opened up a promising window to address the drawbacks of cancer detection and treatment. A wide range of engineered nanomaterials and nanoplatforms with different shapes, sizes, and composition has been developed for various biomedical applications. Nanomaterials have been increasingly used in various applications in bioimaging, diagnosis, and therapy of cancers. Recently, numerous multifunctional and smart nanoparticles with the ability of simultaneous diagnosis and targeted cancer therapy have been reported. The multidisciplinary attempts led to the development of several exciting clinically approved nanotherapeutics. The nanobased materials and devices have also been used extensively to develop point-of-care and highly sensitive methods of cancer detection. In this review article, the most significant achievements and latest advances in the nanomaterials development for cancer nanomedicine are critically discussed. In addition, the future perspectives of this field are evaluated.
Collapse
Affiliation(s)
- Abolghasem Abbasi Kajani
- Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran
| | - Shaghayegh Haghjooy Javanmard
- Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran
| | - Mohsen Asadnia
- School of Engineering, Faculty of Science and Engineering, Macquarie University, Sydney, New South Wales 2109, Australia
| | - Amir Razmjou
- Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan 73441-81746, Iran
- UNESCO Centre for Membrane Science and Technology, School of Chemical Engineering, University of New South Wales, Sydney, New South Wales 2052, Australia
- Centre for Technology in Water and Wastewater, University of Technology Sydney, Sydney, New South Wales 2007, Australia
| |
Collapse
|
7
|
Demin AM, Pershina AG, Minin AS, Brikunova OY, Murzakaev AM, Perekucha NA, Romashchenko AV, Shevelev OB, Uimin MA, Byzov IV, Malkeyeva D, Kiseleva E, Efimova LV, Vtorushin SV, Ogorodova LM, Krasnov VP. Smart Design of a pH-Responsive System Based on pHLIP-Modified Magnetite Nanoparticles for Tumor MRI. ACS APPLIED MATERIALS & INTERFACES 2021; 13:36800-36815. [PMID: 34324807 DOI: 10.1021/acsami.1c07748] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Magnetic Fe3O4 nanoparticles (MNPs) are often used to design agents enhancing contrast in magnetic resonance imaging (MRI) that can be considered as one of the efficient methods for cancer diagnostics. At present, increasing the specificity of the MRI contrast agent accumulation in tumor tissues remains an open question and attracts the attention of a wide range of researchers. One of the modern methods for enhancing the efficiency of contrast agents is the use of molecules for tumor acidic microenvironment targeting, for example, pH-low insertion peptide (pHLIP). We designed novel organosilicon MNPs covered with poly(ethylene glycol) (PEG) and covalently modified by pHLIP. To study the specific features of the binding of pHLIP-modified MNPs to cells, we also obtained nanoconjugates with Cy5 fluorescent dye embedded in the SiO2 shell. The nanoconjugates obtained were characterized by transmission electron microscopy (TEM), attenuated total reflection (ATR), diffuse reflectance infrared Fourier transform spectroscopy (DRIFTS), dynamic light scattering (DLS), UV and fluorescence spectrometry, thermogravimetric analysis (TGA), CHN elemental analyses, and vibrating sample magnetometry. Low cytotoxicity and high specificity of cellular uptake of pHLIP-modified MNPs at pH 6.4 versus 7.4 (up to 23-fold) were demonstrated in vitro. The dynamics of the nanoconjugate accumulation in the 4T1 breast cancer orthotopically grown in BALB/c mice and MDA-MB231 xenografts was evaluated in MRI experiments. Biodistribution and biocompatibility studies of the obtained nanoconjugate showed no pathological change in organs and in the blood biochemical parameters of mice after MNP administration. A high accumulation rate of pHLIP-modified MNPs in tumor compared with PEGylated MNPs after their intravenous administration was demonstrated. Thus, we propose a promising approach to design an MRI agent with the tumor acidic microenvironment targeting ability.
Collapse
Affiliation(s)
- Alexander M Demin
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), 620108 Yekaterinburg, Russia
| | - Alexandra G Pershina
- Siberian State Medical University, 634050 Tomsk, Russia
- Research School of Chemical and Biomedical Engineering, National Research Tomsk Polytechnic University, 634050 Tomsk, Russia
| | - Artem S Minin
- Mikheev Institute of Metal Physics, Russian Academy of Sciences (Ural Branch), 620990 Yekaterinburg, Russia
| | - Olga Ya Brikunova
- Research School of Chemical and Biomedical Engineering, National Research Tomsk Polytechnic University, 634050 Tomsk, Russia
| | - Aidar M Murzakaev
- Institute of Electrophysics, Russian Academy of Sciences (Ural Branch), 620016 Yekaterinburg, Russia
- Institute of Natural Sciences and Mathematics, Ural Federal University, 620000 Yekaterinburg, Russia
| | | | - Alexander V Romashchenko
- Institute of Cytology and Genetics, Russian Academy of Sciences (Siberian Branch), 630090 Novosibirsk, Russia
| | - Oleg B Shevelev
- Institute of Cytology and Genetics, Russian Academy of Sciences (Siberian Branch), 630090 Novosibirsk, Russia
| | - Mikhail A Uimin
- Mikheev Institute of Metal Physics, Russian Academy of Sciences (Ural Branch), 620990 Yekaterinburg, Russia
| | - Iliya V Byzov
- Mikheev Institute of Metal Physics, Russian Academy of Sciences (Ural Branch), 620990 Yekaterinburg, Russia
| | - Dina Malkeyeva
- Institute of Cytology and Genetics, Russian Academy of Sciences (Siberian Branch), 630090 Novosibirsk, Russia
| | - Elena Kiseleva
- Institute of Cytology and Genetics, Russian Academy of Sciences (Siberian Branch), 630090 Novosibirsk, Russia
| | | | - Sergey V Vtorushin
- Siberian State Medical University, 634050 Tomsk, Russia
- Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634050 Tomsk, Russia
| | | | - Victor P Krasnov
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), 620108 Yekaterinburg, Russia
| |
Collapse
|
8
|
Modification of chemically and physically obtained Fe3O4 magnetic nanoparticles with l-Lys for cell labeling. Russ Chem Bull 2021. [DOI: 10.1007/s11172-021-3205-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Design of SiO2/aminopropylsilane-modified magnetic Fe3O4 nanoparticles for doxorubicin immobilization. Russ Chem Bull 2021. [DOI: 10.1007/s11172-021-3177-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
Della Pelle G, Kostevšek N. Nucleic Acid Delivery with Red-Blood-Cell-Based Carriers. Int J Mol Sci 2021; 22:5264. [PMID: 34067699 PMCID: PMC8156122 DOI: 10.3390/ijms22105264] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Revised: 05/11/2021] [Accepted: 05/12/2021] [Indexed: 12/27/2022] Open
Abstract
Gene therapy has the potential to become a staple of 21st-century medicine. However, to overcome the limitations of existing gene-delivery therapies, that is, poor stability and inefficient and delivery and accumulation of nucleic acids (NAs), safe drug-delivery systems (DDSs) allowing the prolonged circulation and expression of the administered genes in vivo are needed. In this review article, the development of DDSs over the past 70 years is briefly described. Since synthetic DDSs can be recognized and eliminated as foreign substances by the immune system, new approaches must be found. Using the body's own cells as DDSs is a unique and exciting strategy and can be used in a completely new way to overcome the critical limitations of existing drug-delivery approaches. Among the different circulatory cells, red blood cells (RBCs) are the most abundant and thus can be isolated in sufficiently large quantities to decrease the complexity and cost of the treatment compared to other cell-based carriers. Therefore, in the second part, this article describes 70 years of research on the development of RBCs as DDSs, covering the most important RBC properties and loading methods. In the third part, it focuses on RBCs as the NA delivery system with advantages and drawbacks discussed to decide whether they are suitable for NA delivery in vivo.
Collapse
Affiliation(s)
- Giulia Della Pelle
- Department for Nanostructured Materials, Jožef Stefan Institute, Jamova Cesta 39, 1000 Ljubljana, Slovenia;
- Jožef Stefan International Postgraduate School, Jamova Cesta 39, 1000 Ljubljana, Slovenia
| | - Nina Kostevšek
- Department for Nanostructured Materials, Jožef Stefan Institute, Jamova Cesta 39, 1000 Ljubljana, Slovenia;
| |
Collapse
|
11
|
Montané X, Matulewicz K, Balik K, Modrakowska P, Łuczak M, Pérez Pacheco Y, Reig-Vano B, Montornés JM, Bajek A, Tylkowski B. Present trends in the encapsulation of anticancer drugs. PHYSICAL SCIENCES REVIEWS 2021. [DOI: 10.1515/psr-2020-0080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Different nanomedicine devices that were developed during the recent years can be suitable candidates for their application in the treatment of various deadly diseases such as cancer. From all the explored devices, the nanoencapsulation of several anticancer medicines is a very promising approach to overcome some drawbacks of traditional medicines: administered dose of the drugs, drug toxicity, low solubility of drugs, uncontrolled drug delivery, resistance offered by the physiological barriers in the body to drugs, among others. In this chapter, the most important and recent progress in the encapsulation of anticancer medicines is examined: methods of preparation of distinct nanoparticles (inorganic nanoparticles, dendrimers, biopolymeric nanoparticles, polymeric micelles, liposomes, polymersomes, carbon nanotubes, quantum dots, and hybrid nanoparticles), drug loading and drug release mechanisms. Furthermore, the possible applications in cancer prevention, diagnosis, and cancer therapy of some of these nanoparticles have been highlighted.
Collapse
Affiliation(s)
- Xavier Montané
- Departament de Química Analítica i Química Orgànica , Universitat Rovira i Virgili Facultat de Quimica , Carrer Marcel·lí Domingo s/n, 43007, Tarragona , Spain
| | - Karolina Matulewicz
- Department of Tissue Engineering Chair of Urology , Nicolaus Copernicus University in Toruń Ludwik Rydygier Collegium Medicum in Bydgoszcz , Karlowicza St. 24, 85-092, Bydgoszcz , Poland
| | - Karolina Balik
- Department of Tissue Engineering Chair of Urology , Nicolaus Copernicus University in Toruń Ludwik Rydygier Collegium Medicum in Bydgoszcz , Karlowicza St. 24, 85-092, Bydgoszcz , Poland
| | - Paulina Modrakowska
- Department of Tissue Engineering Chair of Urology , Nicolaus Copernicus University in Toruń Ludwik Rydygier Collegium Medicum in Bydgoszcz , Karlowicza St. 24, 85-092, Bydgoszcz , Poland
| | - Marcin Łuczak
- Wrzesińskiego Pułku Piechoty we Wrześni , Samorządowa Szkoła Podstawowa nr 1 im. 68 , 62-300, Września , Poland
| | - Yaride Pérez Pacheco
- Departament d’Enginyeria Química , Universitat Rovira i Virgili Escola Tècnica Superior d’Enginyeria Química , Av. Països Catalans, 26, 43007, Tarragona , Spain
| | - Belen Reig-Vano
- Departament d’Enginyeria Química , Universitat Rovira i Virgili Escola Tècnica Superior d’Enginyeria Química , Av. Països Catalans, 26, 43007, Tarragona , Spain
| | - Josep M. Montornés
- Chemical Unit , Eurecat Centre Tecnològic de Catalunya , Carrer Marcel·lí Domingo, s/n,43007, Tarragona , Spain
| | - Anna Bajek
- Department of Tissue Engineering Chair of Urology , Nicolaus Copernicus University in Toruń Ludwik Rydygier Collegium Medicum in Bydgoszcz , Karlowicza St. 24, 85-092, Bydgoszcz , Poland
| | - Bartosz Tylkowski
- Chemical Unit , Eurecat Centre Tecnològic de Catalunya , Carrer Marcel·lí Domingo, s/n,43007, Tarragona , Spain
| |
Collapse
|
12
|
Khot VM, Salunkhe AB, Pricl S, Bauer J, Thorat ND, Townley H. Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance. Drug Discov Today 2020; 26:724-739. [PMID: 33359624 DOI: 10.1016/j.drudis.2020.12.016] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Revised: 11/13/2020] [Accepted: 12/17/2020] [Indexed: 02/07/2023]
Abstract
Cancer cell resistance to chemotherapeutics (chemoresistance) poses a significant clinical challenge that oncology research seeks to understand and overcome. Multiple anticancer drugs and targeting agents can be incorporated in nanomedicines, in addition to different treatment modalities, forming a single nanoplatform that can be used to address tumor chemoresistance. Nanomedicine-driven molecular assemblies using nucleic acids, small interfering (si)RNAs, miRNAs, and aptamers in combination with stimuli-responsive therapy improve the pharmacokinetic (PK) profile of the drugs and enhance their accumulation in tumors and, thus, therapeutic outcomes. In this review, we highlight nanomedicine-driven molecular targeting and therapy combination used to improve the 3Rs (right place, right time, and right dose) for chemoresistant tumor therapies.
Collapse
Affiliation(s)
- Vishwajeet M Khot
- Department of Medical Physics, Center for Interdisciplinary Research, D.Y. Patil Education Society (Institution Deemed to be University), Kolhapur 416006, MS, India.
| | | | - Sabrina Pricl
- MolBNL@UniTS-DEA University of Trieste, Piazzale Europa 1, 34127 Trieste, Italy; Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-137 Lodz, Poland
| | - Joanna Bauer
- Department of Biomedical Engineering, Faculty of Fundamental Technology, Wroclaw University of Science and Technology, 50-370, Wroclaw, Poland
| | - Nanasaheb D Thorat
- Nuffield Department of Women's & Reproductive Health, Division of Medical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK; Department of Engineering Science, University of Oxford, South Parks Road, Oxford, OX1 3PJ, UK.
| | - Helen Townley
- Nuffield Department of Women's & Reproductive Health, Division of Medical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK; Department of Engineering Science, University of Oxford, South Parks Road, Oxford, OX1 3PJ, UK
| |
Collapse
|